The Wall Street Journal

Also in WSJ.com:

International Editions

Market Data

Clovis Oncology Inc. CLVS (U.S.: Nasdaq)

View All companies

REAL TIME 2:00 PM ET 08/22/14
^$43.8616 USD
1.9216 4.58%
Volume 320,067

Volume 320,067
65 Day Avg Vol 862,330
1 Day Range 41.66 - 43.87
52 Week Range 35.33 - 93.33 (08/04/14 - 03/06/14)

Compare

Compare to Benchmark:
DJIA
S&P 500
GLOBAL DOW
NASDAQ
Health Care

Today's Open 41.98
Prior Day Close 41.94 (08/21/14)

Performance Today
CLVS 4.58%
DJIA -0.08%
S&P Mid Cap 400 0.11%
Health Care 0.23%

Latest News Clovis Oncology Inc.(CLVS)

- 08/07/14
- Press Release
Clovis Oncology Announces Second Quarter 2014 Operating Results
- Press Release
- 07/30/14
- Press Release
Conference Call Schedules, Publication of Study Results, and Public Offer Pricing - Research Reports on Medivation, Keryx, Amicus, AGTC and Clovis
- Press Release
- 07/21/14
- Press Release
Clovis Oncology to Announce Second Quarter 2014 Financial Results and Host Webcast Conference Call on August 7
- Press Release
- 07/21/14
- Barron's
Top Biotech Picks for Q2 Earnings
- Barron's
- 07/17/14
- Press Release
Leadership Appointments, Earnings Conference Calls, Milestone Payments, and Technical Updates - Analyst Notes on Illumina, Alexion, Incyte, Clovis and Keryx
- Press Release
- 07/08/14
- Press Release
Patient Enrollments, Board Appointments, Acquisitions, and Technical Updates - Analyst Notes on Questcor, Synta, Clovis, Alnylam and Intrexon
- Press Release
- 06/27/14
- Press Release
Biotechnology Equities Movers and Shakers -- Research on ZIOPHARM Oncology, Clovis Oncology, Arrowhead Research, and NPS Pharma
- Press Release
- 06/23/14
- Press Release
Clovis Oncology Announces First Patient Enrolled in TIGER2 Study
- Press Release
- 06/18/14
- Press Release
Critical Alerts For NTELOS, WebMD, Clovis Oncology, Vodafone, and Procter & Gamble Released By InvestorsObserver
- Press Release
- 06/16/14
- Press Release
Clinical Trial Results, Milestone Payments, New Board Members, and Executive Appointments - Analyst Notes on Cubist, Clovis, Ligand, Bio-Techne and Repligen
- Press Release
- 06/16/14
- Press Release
Clovis Oncology Announces First Patient Enrolled in RUCAPANC Study
- Press Release
- 06/05/14
- Dow Jones Newswires
Clovis Oncology Raised to Buy From Hold by Stifel Nicolaus
- Dow Jones Newswires
- 06/03/14
- Dow Jones Newswires
Clovis Oncology Cut to Neutral From Buy by Citigroup
- Dow Jones Newswires
- 05/31/14
- Press Release
Clovis Oncology Announces Encouraging Data from Phase 1/2a Study Evaluating Lucitanib in Advanced Solid Tumors
- Press Release
- 05/31/14
- Press Release
Clovis Oncology's Phase 1 Study of Rucaparib Demonstrates Compelling Clinical Activity and Safety in Patients with Solid Tumors
- Press Release
- 05/31/14
- Press Release
Clovis Oncology's CO-1686 Demonstrates Compelling Clinical Activity and Progression-free Survival (PFS) in Updated Phase 1/2 Study Results in Patients with EGFR-Mutant Non-small Cell Lung Cancer (NSCLC)
- Press Release
- 05/30/14
- Press Release
Equities Updates on Top Gainers -- Research on Comstock Resources, Zogenix, Mercadolibre, and Clovis Oncology
- Press Release
- 05/24/14
- Barron's
Charting the Market
- Barron's
- 05/22/14
- Press Release
Financial Results, Data Presentations, and Breakthrough Therapy Designation - Analyst Notes on Insys, Seattle Genetics, Cubist, Celldex and Clovis
- Press Release
- 05/21/14
- Press Release
Critical Alerts For JC Penney, Vipshop, Dendreon, Clovis Oncology, and Smith & Wesson Released By InvestorsObserver
- Press Release
- 05/20/14
- Dow Jones Newswires
U.S. Hot Stocks: Hot Stocks to Watch
- Dow Jones Newswires
- 05/19/14
- Dow Jones Newswires
Clovis Shares Rise As Lung Cancer Treatment Receives FDA Breakthrough Therapy Status
- Dow Jones Newswires
- 05/19/14
- Press Release
Clovis Oncology Receives Breakthrough Therapy Designation for CO-1686 for the Treatment of Second-line EGFR Mutant Non-small Cell Lung Cancer (NSCLC) in Patients with the T790M Mutation
- Press Release
- 05/19/14
- Press Release
Critical Alerts For eBay, SunPower, EMC, Clovis Oncology, and Vale Released By InvestorsObserver
- Press Release
- 05/14/14
- Press Release
Clovis Oncology Announces Clinical Data to Be Presented at 2014 ASCO Annual Meeting
- Press Release
- 05/09/14
- Press Release
Technical Updates on Biotech Stocks -- Research on Alexion Pharma, Acorda Therapeutics, Clovis Oncology, and Sangamo BioSciences
- Press Release
- 03/27/14
- Dow Jones Newswires
U.S. Hot Stocks: Hot Stocks to Watch
- Dow Jones Newswires
- 03/27/14
- WSJ Blogs
Stocks to Watch: Citigroup, GameStop, Winnebago
- WSJ Blogs
- 03/27/14
- Dow Jones Newswires
Clovis Shares Jump on Positive Results From Lung Cancer Study
- Dow Jones Newswires
- 03/04/14
- MarketWatch.com
Charting a firmly-grounded, bull-market trend
- MarketWatch.com
- 01/10/14
- WSJ Blogs
Intercept Pharmaceuticals: The Mother of All Momentum Stocks
- WSJ Blogs
- 11/12/13
- Barron's
Health-Care Stocks: Where to Find Value
- Barron's

Key Stock Data

P/E Ratio (TTM): The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing 12 month period.
Earnings Per Share (TTM): A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding.
Market Capitalization: Reflects the total market value of a company. Market Cap is calculated by multiplying the number of shares outstanding by the stock's price. For companies with multiple common share classes, market capitalization includes both classes.
Shares Outstanding: Number of shares that are currently held by investors, including restricted shares owned by the company's officers and insiders as well as those held by the public.
Public Float: The number of shares in the hands of public investors and available to trade. To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded.
Dividend Yield: A company's dividend expressed as a percentage of its current stock price.

Key Stock Data

P/E Ratio (TTM)
N/A
EPS (TTM)
^$-3.54
Market Cap
^$1.42 B
Shares Outstanding
33.91 M
Public Float
24.16 M
Yield
CLVS has not issued dividends in more than 1 year.
Latest Dividend
N/A
Ex-Dividend Date
N/A

Shares Sold Short: The total number of shares of a security that have been sold short and not yet repurchased.
Change from Last: Percentage change in short interest from the previous report to the most recent report. Exchanges report short interest twice a month.
Percent of Float: Total short positions relative to the number of shares available to trade.

Short Interest

Shares Sold Short
3.97 M (07/31/2014)
Change from Last
-3.18%
Percent of Float
16.43%

Money Flow Uptick/Downtick Ratio: Money flow measures the relative buying and selling pressure on a stock, based on the value of trades made on an "uptick" in price and the value of trades made on a "downtick" in price. The up/down ratio is calculated by dividing the value of uptick trades by the value of downtick trades. Net money flow is the value of uptick trades minus the value of downtick trades. Our calculations are based on comprehensive, delayed quotes.

Stock Money Flow

Uptick/Downtick Trade Ratio

0 2

1.34

Net Money Flow ($)
+1.12 M

Money flow gives a snapshot of relative buying and selling pressure in a stock. A ratio above one suggests greater buying pressure, below one suggests greater selling.

Competitors (CLVS)

Company	Change	P/E (TTM)
002004 Huapont-Nutrichem Co. Ltd. A	-1.40% -0.28	31.35
002424 Guizhou Bailing Group Pharmaceutical Co. Ltd.	+0.03% +0.01	58.00
WX WuXi Pharmatech (Cayman) Inc. ADS	+0.30% +0.11	24.31
600557 Jiangsu Kanion Pharmaceutical Co. Ltd.	+0.78% +0.21	42.03
300026 Tianjin Chase Sun Pharmaceutical Co. Ltd.	+0.18% +0.05	39.64
DIA DiaSorin S.p.A.	-1.30% -0.40	20.10
600252 Guangxi Wuzhou Zhongheng Group Co. Ltd. A	+0.94% +0.12	16.44
600436 Zhangzhou Pientzehuang Pharmaceutical Co. Ltd.	-0.31% -0.26	31.69
THRX Theravance Inc.	+0.09% +0.02	-
GBT Guerbet S.A.	+0.43% +0.15	19.05

Competitor Data Provided By: capital cube

Profile (CLVS)

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. The company has three product candidates in its clinical development pipeline: CO-1686,...

2525 28th Street
Boulder Colorado 80301
United States

Employees 74

Sector Biotechnology
Sales or Revenue -

Industry Health Care
1Y Sales Change -

Fiscal Year Ends December 31 Download Reports

Jim Barrett Independent Chairman

Patrick J. Mahaffy President, Chief Executive Officer & Director

Erle T. Mast Chief Financial Officer, Secretary & Executive VP

Andrew R. Allen Chief Medical Officer & EVP-Clinical Development

Research & Ratings Clovis Oncology Inc.(CLVS)

Per-Share Earnings, Actuals and Estimates

CLVS will report Q3 earnings on 10/30/2014

Actual Analyst Range Consensus

0.50 0.00 -0.50 -1.00 -1.50

Actual -0.68 -0.68	Actual -0.92 -0.78	Actual -0.91 -0.85	Actual -1.03 -0.96		-1.01	-1.11
Q32013	Q4	Q12014	Q2		Q3	Q4

Q3 2014 Estimate Trends
Current:	^$-1.01
1 month ago:	^$-0.97
3 months ago:	^$-0.99

Q4 2014 Estimate Trends
Current:	^$-1.11
1 month ago:	^$-1.07
3 months ago:	^$-1.08

FY 2014 Estimate Trends
Current:	^$-3.98
1 month ago:	^$-3.84
3 months ago:	^$-3.89

FY 2015 Estimate Trends
Current:	^$-4.99
1 month ago:	^$-4.83
3 months ago:	^$-4.69

Financials Clovis Oncology Inc.(CLVS)

Net Income

0 -9M -18M -27M -36M

Jun 2013 Sep 2013 Dec 2013 Mar 2014 Jun 2014

Jun 2014

5-quarter trend

Net Income Growth

-79.74%

Sales or Revenue

Sales or Revenue Growth

EBITDA

-33.62 M

Actual -2.95 -2.77	-3.98	-4.99	-5.47
FY 2013	FY 2014	FY 2015	FY 2016

Clovis Oncology Inc. CLVS (U.S.: Nasdaq)

REAL TIME 2:00 PM ET 08/22/14

Volume 320,067

Key Stock Data

P/E Ratio (TTM)

EPS (TTM)

Market Cap

Shares Outstanding

Public Float

Yield

Latest Dividend

Ex-Dividend Date

Short Interest

Shares Sold Short

Change from Last

Percent of Float

Stock Money Flow

Uptick/Downtick Trade Ratio

Net Money Flow ($)

Competitors (CLVS)

Per-Share Earnings, Actuals and Estimates

Net Income

Customer Service

Policy

Ads

Tools & Features

More